The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling

[1] Liu Y(2023)Advances in immunotherapy for triple-negative breast cancer Mol Cancer 22 145-1350

[2] Hu Y(2023)Recent advances in targeted strategies for triple-negative breast cancer J Hematol Oncol 16 100-1342

[3] Xue J(2023)Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics Cureus 15 e44582-567

[4] Li J(2023)Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients Genes Dis 10 1318-2058

[5] Yi J(2023)PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis Front Immunol 14 1206689-6388

[6] Bu J(2023)TIGIT, a novel immune checkpoint therapy for melanoma Cell Death Dis 14 466-1439

[7] Zhang Z(2023)Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer Front Oncol 13 1165257-777

[8] Qiu P(2011)Cutting edge: TIGIT has T cell-intrinsic inhibitory functions J Immunol 186 1338-338

[9] Gu X(2003)Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule J Exp Med 198 557-196

[10] Zhu S(2015)TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients J Clin Invest 125 2046-692

[1] Liu Y(2023)Advances in immunotherapy for triple-negative breast cancer Mol Cancer 22 145-1350

[2] Hu Y(2023)Recent advances in targeted strategies for triple-negative breast cancer J Hematol Oncol 16 100-1342

[3] Xue J(2023)Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics Cureus 15 e44582-567

[4] Li J(2023)Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients Genes Dis 10 1318-2058

[5] Yi J(2023)PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis Front Immunol 14 1206689-6388

[6] Bu J(2023)TIGIT, a novel immune checkpoint therapy for melanoma Cell Death Dis 14 466-1439

[7] Zhang Z(2023)Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer Front Oncol 13 1165257-777

[8] Qiu P(2011)Cutting edge: TIGIT has T cell-intrinsic inhibitory functions J Immunol 186 1338-338

[9] Gu X(2003)Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule J Exp Med 198 557-196

[10] Zhu S(2015)TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients J Clin Invest 125 2046-692